Côte d'Ivoire - Women's share of population ages 15+ living with HIV (%)

Women's share of population ages 15+ living with HIV (%) in Côte d'Ivoire was 65.80 as of 2020. Its highest value over the past 30 years was 65.80 in 2020, while its lowest value was 50.70 in 1990.

Definition: Prevalence of HIV is the percentage of people who are infected with HIV. Female rate is as a percentage of the total population ages 15+ who are living with HIV.

Source: UNAIDS estimates.

See also:

Year Value
1990 50.70
1991 51.40
1992 52.00
1993 52.60
1994 53.10
1995 53.50
1996 54.00
1997 54.40
1998 54.90
1999 55.30
2000 55.70
2001 56.10
2002 56.50
2003 56.90
2004 57.40
2005 57.80
2006 58.20
2007 58.70
2008 59.20
2009 59.70
2010 60.20
2011 60.70
2012 61.20
2013 61.70
2014 62.30
2015 62.90
2016 63.50
2017 64.10
2018 64.80
2019 65.30
2020 65.80

Limitations and Exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information.

Statistical Concept and Methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.

Aggregation method: Weighted average

Periodicity: Annual

Classification

Topic: Health Indicators

Sub-Topic: Risk factors